Chemours Company (The) (NYSE:CC) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

CC has been the subject of a number of other reports. Citigroup Inc. boosted their target price on shares of Chemours Company (The) from $45.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 4th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $50.00 target price (up from $48.00) on shares of Chemours Company (The) in a research note on Thursday, July 13th. UBS AG raised shares of Chemours Company (The) from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $36.00 to $50.00 in a research note on Monday, August 7th. Susquehanna Bancshares Inc boosted their price target on shares of Chemours Company (The) from $45.00 to $55.00 and gave the stock a “positive” rating in a research note on Monday, May 15th. Finally, ValuEngine raised shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Chemours Company (The) currently has an average rating of “Buy” and a consensus target price of $51.50.

Chemours Company (NYSE CC) opened at 47.53 on Thursday. Chemours Company has a 12 month low of $12.40 and a 12 month high of $51.51. The company has a 50-day moving average price of $45.58 and a 200 day moving average price of $39.32. The firm has a market cap of $8.78 billion, a PE ratio of 31.11 and a beta of 3.63.

Chemours Company (The) (NYSE:CC) last announced its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm posted $0.27 earnings per share. The company’s revenue was up 14.8% on a year-over-year basis. Equities research analysts anticipate that Chemours Company will post $3.51 EPS for the current year.

WARNING: “Chemours Company (The) (CC) Upgraded to “Buy” at BidaskClub” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/24/chemours-company-the-cc-upgraded-to-buy-at-bidaskclub.html.

In related news, insider Paul Kirsch sold 19,036 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $41.42, for a total transaction of $788,471.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider E Bryan Snell sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $46.24, for a total transaction of $462,400.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,536 shares of company stock valued at $1,365,946. Corporate insiders own 1.14% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CC. Teachers Advisors LLC boosted its position in Chemours Company (The) by 2.5% in the fourth quarter. Teachers Advisors LLC now owns 309,248 shares of the specialty chemicals company’s stock valued at $6,831,000 after buying an additional 7,432 shares during the period. Oakbrook Investments LLC bought a new position in Chemours Company (The) during the first quarter valued at $255,000. Retirement Systems of Alabama bought a new position in Chemours Company (The) during the first quarter valued at $9,103,000. James Investment Research Inc. bought a new position in Chemours Company (The) during the first quarter valued at $505,000. Finally, Nationwide Fund Advisors boosted its position in Chemours Company (The) by 262.6% in the first quarter. Nationwide Fund Advisors now owns 413,027 shares of the specialty chemicals company’s stock valued at $15,902,000 after buying an additional 299,121 shares during the period. Institutional investors own 76.51% of the company’s stock.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.